A5090908429- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Migraine and Headache Studies
- Health Systems, Economic Evaluations, Quality of Life
- Botulinum Toxin and Related Neurological Disorders
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cardiovascular Syncope and Autonomic Disorders
- Food Allergy and Anaphylaxis Research
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Statistical Methods in Clinical Trials
- Dermatology and Skin Diseases
- Glaucoma and retinal disorders
- Inflammatory mediators and NSAID effects
- Prostate Cancer Treatment and Research
- SARS-CoV-2 and COVID-19 Research
- Asthma and respiratory diseases
- Economic and Financial Impacts of Cancer
- Drug-Induced Adverse Reactions
- Psoriasis: Treatment and Pathogenesis
- Vaccine Coverage and Hesitancy
- Retinal Diseases and Treatments
RTI Health Solutions
2014-2024
RTI International
2009-2021
Cancer Research And Biostatistics
2019
Triangle
2018
Research Triangle Park Foundation
2010-2014
University of Miami
2009
Article AbstractObjective: With data from the population-based Prevalence of Female Sexual Problems Associated with Distress and Determinants Treatment Seeking (PRESIDE) study, which has previously estimated prevalence sexual problems sexually related personal distress in United States women, disorders desire, arousal, orgasm was re-estimated, taking concurrent depression into consideration.Method: Current defined 3 ways as (1) self-reported symptoms alone, (2) antidepressant medication use...
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool reduce the COVID-19 burden. Vaccine reactogenicity and impact on work productivity/daily activities are recognized as contributing factors vaccine hesitancy. To encourage continued vaccination, more complete understanding of differences in impairment due vaccine-related side effects across currently available vaccines is necessary. The 2019nCoV-406 study (n = 1367) was prospective observational associated...
Despite longstanding recommendations for routine vaccination against influenza; pneumococcal; tetanus, diphtheria, acellular pertussis (Tdap); and herpes zoster (HZ) among the United States general adult population, vaccine uptake remains low. Understanding factors that influence coverage variability beyond national level are important steps toward developing targeted strategies increasing coverage. A retrospective analysis was conducted using data from Behavioral Risk Factor Surveillance...
In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo ADT significantly improved metastasis-free survival (MFS), overall (OS) and time to pain progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Herein, we present analyses of patient-reported health-related quality life (HRQoL) outcomes.This double-blind, placebo-controlled, phase III trial randomised nmCRPC prostate-specific antigen doubling ≤10 months 600 mg (n =...
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic chronic migraine in routine clinical practice. Background Clinical trials support prophylaxis headache patients with migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study adult treated onabotulinumtoxinA. Data were collected at first injection approximately every three months ≤52 weeks ≤64 data, summarized using descriptive...
Panitumumab monotherapy is approved for chemotherapy-refractory wild-type KRAS metastatic colorectal cancer (mCRC). Patient-reported outcomes—although important in the palliative setting—have not been reported this patient population. In a phase 3 trial (n = 463), patients with mCRC were randomized 1:1 to panitumumab plus best supportive care (BSC) or BSC alone. outcomes assessed using NCCN/FACT CRC Symptom Index (FCSI) and EQ-5D Index. tumor status was analyzed prospectively defined,...
Objectives . Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, other targeted therapy, also assessed a (ERIVANCE). We examined comparative effectiveness of two drugs using matching-adjusted indirect comparison (MAIC) versus an unadjusted comparison. Methods After comparing trials identifying potential prognostic factors, MAIC conducted adjust...
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance receive updated vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study was conducted examine within the first 2 days after vaccination with either protein-based vaccine (NVX-CoV2373) or an mRNA (BNT162b2 mRNA-1273) individuals who previously completed primary series. Propensity score adjustments were address potential...
5000 Background: DARO is a structurally distinct androgen receptor antagonist for which in vitro and phase 1/2 studies suggest low risk of adverse events (AEs) drug–drug interaction. In the ARAMIS study nmCRPC, metastasis-free survival (MFS) was significantly prolonged vs placebo (PBO) (40.4 18.4 mo; hazard ratio [HR] 0.41; 95% confidence interval [CI] 0.34–0.50; P < 0.001) interim overall (OS) favored (HR 0.71; CI 0.50–0.99; = 0.045). Methods: 1509 pts were randomized 2:1 to 600 mg (two...
A pilot survey described the characteristics of anaphylactic events occurring in an initial set participating U.S. schools during 2013–2014 school year. This was subsequently readministered to large districts, which were underrepresented results. cross-sectional administered that EPIPEN4SCHOOLS® program (Mylan Specialty L.P., Canonsburg, PA) assess events. Data from districts added findings this comprehensive combined analysis. total 1,140 reported among 6,574 responding schools. Of 1,063...
Health-related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post-transplant, when disease symptoms are limited.We assessed HRQoL patients randomised to 26 cycles MT (ixazomib vs placebo) TOURMALINE-MM3 (NCT02181413).The characteristics at study entry were well-balanced between ixazomib (n = 386) and placebo 251) arms. At entry, EORTC QLQ-C30 MY20 scores high for functional scales low symptom comparable with those the...
Abstract Purpose To assess and describe patient-reported outcomes (PROs) in women with locally advanced/unresectable or metastatic breast cancer (aBC/mBC) hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) status receiving palbociclib combination therapy a US real-world setting. Methods A prospective, noninterventional, multicenter longitudinal study was conducted patients initiating treatment for HR − aBC/mBC. PRO data (SF-12; CES-D-10; mood; pain;...
The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [NCT01103323]; CONCUR [NCT01584830]), advanced gastrointestinal stromal (GIST) (GRID [NCT01271712]), hepatocellular carcinoma (HCC) (RESORCE [NCT01774344]). objective this post hoc exploratory analysis was to explore the impact on delaying health-related quality life (HRQOL) deterioration across these types. HRQOL data (assessed with...
We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER was identified 356/506 patients. In ER-positive tumours, median overall survival enrolment 17.7 months CD versus 12.5 (hazard ratio [HR] 0.65, 95% confidence interval...
1024 Background: Previous studies in pts with MBC have shown that women ER+ tumors a longer survival time compared to ER- tumors. An exploratory analysis was conducted describe the relationship between and ER status among treated combination therapy consisting of C+D. Methods: This used data from an open-label, randomized phase III trial C+D vs D alone advanced and/or MBC. Survival investigate effect baseline primary metastatic on overall (OS). defined as positive if for any tumor, negative...